-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the implementation of a series of policies such as "generic drug consistency evaluation", "quantity procurement", and "medical insurance negotiation", the pharmaceutical industry has begun to face more and more changes
.
It is worth noting that in this context, many Chinese pharmaceutical companies have begun to pay more and more attention to R&D investment in innovative drugs in order to improve their market competitiveness
.
At present, public information shows that a large number of pharmaceutical companies are investing in R&D continuously
.
For example, according to the "Statistical Bulletin of National Science and Technology Expenditures in 2020" issued by the National Bureau of Statistics, the Ministry of Science and Technology and the Ministry of Finance, China's R&D expenditure in 2020 has reached 2439.
31 billion yuan, of which the R&D expenditure in the pharmaceutical manufacturing industry will reach 784.
6 100 million yuan
.
Among them, BeiGene's R&D investment in 2020 hit a record high
.
According to financial report data, its annual research and development expenses totaled 1.
29 billion US dollars (equivalent to approximately 8.
3 billion yuan), an increase of 39.
11% year-on-year, accounting for approximately 412.
73% of revenue
.
It is understood that the increase in BeiGene's research and development expenses is mainly used for the ongoing and newly launched late-stage critical clinical trials continued to increase, and the research and development expenses related to the advance payment of authorized drug candidates
.
It is worth mentioning that in the first half of this year, BeiGene invested US$677 million (approximately 4.
38 billion yuan) in research and development
.
As of the end of the reporting period, the company's global clinical development team has more than 1,700 people, with about 50 drugs or drug candidates in commercialization or clinical development stages, and more than 95 clinical trials in progress or planned
.
In addition, Hengrui Medicine's R&D expenses in 2020 are also increasing rapidly
.
According to data from Hengrui's financial report, from 2018 to 2020, Hengrui's R&D investment was 2.
670 billion yuan, 3.
896 billion yuan, and 4.
989 billion yuan, respectively.
The three-year R&D expenses reached 11.
55 billion yuan
.
In addition to increasing capital investment, the number and proportion of Hengrui R&D personnel are also increasing year by year
.
Data shows that the number of R&D personnel of Hengrui Pharmaceuticals in 2020 has increased from 3,116 in 2017 to 4,721 in 2020, and the proportion of the total number of employees has also increased from 14.
83% in 2017 to 16.
33%
.
In fact, it can be seen from the above that as the cost of pharmaceutical research and development is increasing year by year, and the medical reform policies such as "purchasing with volume" enter the implementation period, local pharmaceutical companies have moved from the past development model of "focusing on sales and neglecting R&D" and are accelerating their transformation.
Stage
.
More and more pharmaceutical companies have realized that only by focusing on R&D can they live better, so they are constantly increasing their investment in R&D and innovation
.
In fact, since the beginning of this year, the cost of innovation and R&D input for major pharmaceutical companies has continued to rise
.
For example, as listed biomedical companies on the Sci-tech Innovation Board continued to increase R&D investment in the first half of the year, the total R&D investment amount has reached 5.
079 billion yuan, an increase of 50% from the 3.
387 billion yuan in the same period last year
.
Among them, seven companies including Junshi Biology and Cansino Biology invested more than 100 million yuan in R&D in the first half of the year.
The R&D expenses of five companies including Oriental Biology increased by more than 100% year-on-year.
The R&D expense ratios of Zejing Pharmaceutical and Frontier Bio 200%
.
In general, domestic pharmaceutical companies attach great importance to innovation in 2021.
With continuous R&D investment, the industry expects that news of new drugs approval will continue to be heard, bringing more gospel to the majority of patients
.
.
It is worth noting that in this context, many Chinese pharmaceutical companies have begun to pay more and more attention to R&D investment in innovative drugs in order to improve their market competitiveness
.
At present, public information shows that a large number of pharmaceutical companies are investing in R&D continuously
.
For example, according to the "Statistical Bulletin of National Science and Technology Expenditures in 2020" issued by the National Bureau of Statistics, the Ministry of Science and Technology and the Ministry of Finance, China's R&D expenditure in 2020 has reached 2439.
31 billion yuan, of which the R&D expenditure in the pharmaceutical manufacturing industry will reach 784.
6 100 million yuan
.
Among them, BeiGene's R&D investment in 2020 hit a record high
.
According to financial report data, its annual research and development expenses totaled 1.
29 billion US dollars (equivalent to approximately 8.
3 billion yuan), an increase of 39.
11% year-on-year, accounting for approximately 412.
73% of revenue
.
It is understood that the increase in BeiGene's research and development expenses is mainly used for the ongoing and newly launched late-stage critical clinical trials continued to increase, and the research and development expenses related to the advance payment of authorized drug candidates
.
It is worth mentioning that in the first half of this year, BeiGene invested US$677 million (approximately 4.
38 billion yuan) in research and development
.
As of the end of the reporting period, the company's global clinical development team has more than 1,700 people, with about 50 drugs or drug candidates in commercialization or clinical development stages, and more than 95 clinical trials in progress or planned
.
In addition, Hengrui Medicine's R&D expenses in 2020 are also increasing rapidly
.
According to data from Hengrui's financial report, from 2018 to 2020, Hengrui's R&D investment was 2.
670 billion yuan, 3.
896 billion yuan, and 4.
989 billion yuan, respectively.
The three-year R&D expenses reached 11.
55 billion yuan
.
In addition to increasing capital investment, the number and proportion of Hengrui R&D personnel are also increasing year by year
.
Data shows that the number of R&D personnel of Hengrui Pharmaceuticals in 2020 has increased from 3,116 in 2017 to 4,721 in 2020, and the proportion of the total number of employees has also increased from 14.
83% in 2017 to 16.
33%
.
In fact, it can be seen from the above that as the cost of pharmaceutical research and development is increasing year by year, and the medical reform policies such as "purchasing with volume" enter the implementation period, local pharmaceutical companies have moved from the past development model of "focusing on sales and neglecting R&D" and are accelerating their transformation.
Stage
.
More and more pharmaceutical companies have realized that only by focusing on R&D can they live better, so they are constantly increasing their investment in R&D and innovation
.
In fact, since the beginning of this year, the cost of innovation and R&D input for major pharmaceutical companies has continued to rise
.
For example, as listed biomedical companies on the Sci-tech Innovation Board continued to increase R&D investment in the first half of the year, the total R&D investment amount has reached 5.
079 billion yuan, an increase of 50% from the 3.
387 billion yuan in the same period last year
.
Among them, seven companies including Junshi Biology and Cansino Biology invested more than 100 million yuan in R&D in the first half of the year.
The R&D expenses of five companies including Oriental Biology increased by more than 100% year-on-year.
The R&D expense ratios of Zejing Pharmaceutical and Frontier Bio 200%
.
In general, domestic pharmaceutical companies attach great importance to innovation in 2021.
With continuous R&D investment, the industry expects that news of new drugs approval will continue to be heard, bringing more gospel to the majority of patients
.
